Clinical Trial

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-13.
Status change: Not Yet Recruiting → Recruiting 2025-11-27
Trial Details
NCT Number NCT07229729
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Non-small Cell Lung Cancer
Enrollment 300 participants
Start Date 2025-11-24
Primary Completion 2026-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-01